Genscript Biotech Announces Legend Biotech’s Q4 and FY2025 Results: Key Highlights for Investors

Genscript Biotech Corporation (HKEX: 1548) has released a voluntary announcement highlighting the financial results for the fourth quarter and the full year ended 31 December 2025 of its associate, Legend Biotech Corporation. Legend is listed on the Nasdaq Global Select Market via American Depository Shares (ADS). The results were officially filed with the US Securities and Exchange Commission (SEC) on 10 March 2026.

Key Points from the Announcement

• Financial Results Disclosure: The announcement specifically pertains to Legend Biotech Corporation’s financial results for Q4 and the full year 2025. These results were formally submitted to the SEC and are accessible through the SEC’s official website.
• Nature of Announcement: This is a voluntary disclosure by Genscript Biotech. It is intended to update shareholders and investors about the performance of its associate, Legend Biotech, rather than Genscript’s own financial results.
• Access to Full Details: Investors and shareholders are encouraged to review the full Form 6-K filing on the SEC’s website to gain a comprehensive understanding of Legend’s financial position and recent business highlights.
• Leadership Statement: The announcement is issued by Robin Meng, Chairman and Executive Director of Genscript Biotech Corporation, and lists the current board members, which includes a mix of executive and independent non-executive directors.

Important Information for Shareholders

• Potential Price Sensitivity: While the announcement itself does not disclose Genscript’s own financials, the performance of Legend Biotech could have an indirect impact on Genscript’s valuation and share price, given that Legend is an associate. Investors should monitor Legend’s developments closely.
• Investment Risks: Shareholders and potential investors are explicitly advised to exercise caution and pay attention to investment risks when dealing in the securities of Genscript Biotech, especially as the update relates to an associate and not directly to Genscript’s own business.
• Market Impact: The announcement underlines that Legend’s financial results may be of significant interest, given its public listing in the US and the potential for news flow from Legend to influence both companies’ share prices.

Actionable Steps for Investors

1. Review Legend Biotech’s full Q4 and FY2025 financial results on the SEC website for detailed insight.
2. Assess how Legend’s performance could impact Genscript Biotech’s financial position and valuation.
3. Remain vigilant for further announcements from Genscript Biotech, particularly if Legend’s results signal strong growth, new business highlights, or material changes that could affect Genscript’s future earnings.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own research and consult with professional advisers before making any investment decisions. The content herein is based on publicly available disclosures as of 10 March 2026 and may be subject to change.

View GENSCRIPT BIO Historical chart here